ERBB2 and breast cancer: The effect on cancer cell viability of the gold(I) compounds reported in Scheme 1 was first estimated by MTT assay on SKBR3 cells, representing the HER2-positive breast cancer subtype, after drug treatment for 72 h (Figure 1S).